IP/IV Paclitaxel plus S-1 regimen

OS extended by 5.5 months

Adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 significantly prolongs overall survival in gastric cancer patients with peritoneal metastasis.

Yan, Chao · Yang, Zhongyin · Shi, Zheng · Lu, Sheng · Shi, Min · Nie, Mingming · Chen, Jian · Wu, Dan · Mou, Yiping · Xu, Yunyun · Wang, Yanong · Liu, Xiaowen · Cao, Hui · Gu, Jiayi · Yu, Jiren · Liu, Kai · Liu, Xinchun · Zhang, Jun · Yin, Kai · Zhu, Zhenggang

JAMA Oncology 2026

Specifications

Median overall survival (IP group)
{'zh': '19.4', 'en': '19.4'} months
Median overall survival (PS group)
{'zh': '13.9', 'en': '13.9'} months
Overall survival hazard ratio
{'zh': '0.67', 'en': '0.67'}
Median progression-free survival (IP group)
{'zh': '11.2', 'en': '11.2'} months
Median progression-free survival (PS group)
{'zh': '7.2', 'en': '7.2'} months
Progression-free survival hazard ratio
{'zh': '0.72', 'en': '0.72'}
Grade 3-4 adverse event rate (IP group)
{'zh': '38.5', 'en': '38.5'} %
Grade 3-4 adverse event rate (PS group)
{'zh': '41.9', 'en': '41.9'} %

Advantages

Significantly prolongs survival

Median overall survival was extended from 13.9 to 19.4 months, with a hazard ratio of 0.67, and progression-free survival also improved significantly.

No increased severe toxicity

Grade 3 or 4 adverse events occurred in 38.5% of the IP group versus 41.9% in the PS group, and no treatment-related deaths occurred, indicating an acceptable safety profile.

Clinically applicable

The regimen uses approved drugs with a defined intraperitoneal delivery protocol, validated in 9 hospitals, supporting adoption as first-line therapy.

Applications